Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Farrell

Showing results (61-70 of 172) with videos related to

Pageof 18
Sort By:
Diagnostic Microbiology and Infectious Disease|September 30, 2015
Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwideHelio S Sader, Paul R Rhomberg, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|November 17, 2009
Linezolid surveillance program results for 2008 (LEADER Program for 2008)David J Farrell, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy|June 13, 2012
Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitalsRodrigo E Mendes, Lalitagauri M Deshpande, Andrew J Costello, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2011
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strainsDavid J Farrell, Lisa C Liverman, Douglas J Biedenbach, et al.
Diagnostic Microbiology and Infectious Disease|October 13, 2014
Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal diseaseSteven L Barriere, David J Farrell, Paul R Rhomberg, et al.
Diagnostic Microbiology and Infectious Disease|February 5, 2014
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)Helio S Sader, David J Farrell, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy|February 5, 2014
Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012)Helio S Sader, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease|November 14, 2012
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010)David J Farrell, Robert K Flamm, Ronald N Jones, et al.
International Journal of Antimicrobial Agents|January 14, 2014
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec typesDavid J Farrell, Robert K Flamm, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|July 24, 2012
Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strainsDouglas J Biedenbach, Lisa L Turner, Ronald N Jones, et al.
Pageof 18

Showing results (61-70 of 172) with videos related to

Sort By:
Pageof 18
Diagnostic Microbiology and Infectious Disease|September 30, 2015
Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwideHelio S Sader, Paul R Rhomberg, David J Farrell, et al.
Diagnostic Microbiology and Infectious Disease|November 17, 2009
Linezolid surveillance program results for 2008 (LEADER Program for 2008)David J Farrell, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy|June 13, 2012
Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitalsRodrigo E Mendes, Lalitagauri M Deshpande, Andrew J Costello, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2011
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strainsDavid J Farrell, Lisa C Liverman, Douglas J Biedenbach, et al.
Diagnostic Microbiology and Infectious Disease|October 13, 2014
Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal diseaseSteven L Barriere, David J Farrell, Paul R Rhomberg, et al.
Diagnostic Microbiology and Infectious Disease|February 5, 2014
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)Helio S Sader, David J Farrell, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy|February 5, 2014
Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012)Helio S Sader, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease|November 14, 2012
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010)David J Farrell, Robert K Flamm, Ronald N Jones, et al.
International Journal of Antimicrobial Agents|January 14, 2014
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec typesDavid J Farrell, Robert K Flamm, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|July 24, 2012
Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strainsDouglas J Biedenbach, Lisa L Turner, Ronald N Jones, et al.
Pageof 18